Clinical trial
Melphalan and Palifermin in Treating Patients Undergoing An Autologous…
NCT00482846 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00482846 |
|---|---|
| Title | Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma |
| Official title | Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Mucositis, Multiple Myeloma |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment |
| Enrollment | 38 |
| Start date | Jun 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Sep 1, 2012 |
| First posted | Jun 5, 2007 |
| Last update posted | Apr 15, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: